Premium
Review article: acid‐related disease – what are the unmet clinical needs?
Author(s) -
KATZ P. O.,
SCHEIMAN J. M.,
BARKUN A. N.
Publication year - 2006
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2006.02944.x
Subject(s) - medicine , dosing , proton pump inhibitor , intensive care medicine , disease
Summary Proton pump inhibitors have dramatically improved the management options available for patients with acid‐related disorders. In patients with gastro‐oesophageal reflux disease, currently available proton pump inhibitors provide an excellent outcome for the majority; however, they do not provide optimal pH control in many. Proton pump inhibitors co‐therapy reduces, but does not eliminate, the risk of gastrointestinal ulcers and complications in patients taking non‐steroidal anti‐inflammatory drugs, while in patients with upper gastrointestinal bleeding, it may be difficult to reach and maintain the current therapeutic target of intragastric pH of 6–7. This article reviews the effectiveness of current antisecretory therapy in these three acid‐related diseases and areas of unmet clinical need. The potential role of a proton pump inhibitor with an extended duration of action and enhanced acid control from a single daily dose, particularly improved control at night, is discussed. Finally, therapy that could be administered without regard to time of day and/or food intake would offer dosing flexibility and thus have a positive effect on patients’ compliance.